Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, PLW

PHARMANUTRA S.P.A.: NEW LICENCE GRANTED IN THE U.S.A.


PISA, Italy, Jan. 17, 2022 /CNW/ -- PharmaNutra S.p.A. (MTA; Ticker PHN), a company specialising in mineral- and iron-based nutritional supplements and medical devices for muscles and joints, has been granted a patent in the United States for use of Cetylated Fatty Acids (CFA).

The patent, granted with number "US 11,186,536", further consolidates PharmaNutra's intellectual property rights for the use of Cetylated Fatty Acids (CFA), the functional ingredient contained in the Cetilar®-branded formulations for the treatment and prevention of muscular and articular problems. Specifically, the new patent safeguards a series of specific stages in the production process. Above all, it envisages both topical and oral use of CFA-based formulations.

Thanks to the development of patents based on complexes of highly concentrated cetylated fatty acids, in recent years PharmaNutra S.p.A. has become one of the top emerging players on the market for medical devices for the rehabilitation of muscle and joint capacity. The granting of the new patent is further consolidation of the patented technologies of the PharmaNutra group, which in 2020, in the USA, was granted, in order: (i) a process patent for CFA production; (ii) registration of the Cetilar® brand; (iii) GRAS designation for its CFA-based oral formulations.

"Another important step in our conquest of the American market. This is a long and complicated journey which, on completion, will open up new scenarios and ample growth prospects for PharmaNutra and our Cetilar® brand, in particular in a country with huge potential," said Andrea Lacorte, Chairman and co-founder of the PharmaNutra Group.

Contacts:
Investor Relations Pharmanutra, 050 7846500, [email protected]
Gianluca Gracci, Pharmanutra, +39 345 3646330, [email protected]  
Cristina Tronconi, +39 346 0477901, [email protected]
Matteo Russo, +39 347 9834881, [email protected]

Logo - https://mma.prnewswire.com/media/1391450/PharmaNutra_Logo.jpg

SOURCE PharmaNutra S.p.A.


These press releases may also interest you

at 16:05
Immunome, Inc. , a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2023, and provided an overview of recent developments....

at 16:05
Bristol Myers Squibb today announced an update following the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE clinical trial program evaluating Zeposia (ozanimod) in adult patients with moderate to...

at 16:05
Personalis, Inc. , a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10 at 1:30 p.m. Eastern Time. About Personalis, Inc....

at 16:05
Helius Medical Technologies, Inc. ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter and full year ended December...

at 16:05
Achieve Life Sciences, Inc. , a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced fourth quarter and year-end 2023 financial...

at 16:05
Spectral Medical Inc. ("Spectral" or the "Company") , a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2023...



News published on and distributed by: